Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

The small molecule BI-2852 induces a nonfunctional dimer of KRAS.

Tran TH, Alexander P, Dharmaiah S, Agamasu C, Nissley DV, McCormick F, Esposito D, Simanshu DK, Stephen AG, Balius TE.

Proc Natl Acad Sci U S A. 2020 Feb 11. pii: 201918164. doi: 10.1073/pnas.1918164117. [Epub ahead of print] No abstract available.

2.

Membrane interactions of the globular domain and the hypervariable region of KRAS4b define its unique diffusion behavior.

Goswami D, Chen, Yang Y, Gudla PR, Columbus J, Worthy K, Rigby M, Wheeler M, Mukhopadhyay S, Powell K, Burgan W, Wall V, Esposito D, Simanshu D, Lightstone FC, Nissley DV, McCormick F, Turbyville T.

Elife. 2020 Jan 20;9. pii: e47654. doi: 10.7554/eLife.47654. [Epub ahead of print]

3.

Undermining glutaminolysis bolsters chemotherapy while NRF2 promotes chemoresistance in KRAS-driven pancreatic cancers.

Mukhopadhyay S, Goswami D, Adiseshaiah PP, Burgan W, Yi M, Guerin TM, Kozlov SV, Nissley DV, McCormick F.

Cancer Res. 2020 Jan 7. pii: canres.1363.2019. doi: 10.1158/0008-5472.CAN-19-1363. [Epub ahead of print]

PMID:
31911550
4.

Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.

Sherekar M, Han SW, Ghirlando R, Messing S, Drew M, Rabara D, Waybright T, Juneja P, O'Neill H, Stanley CB, Bhowmik D, Ramanathan A, Subramaniam S, Nissley DV, Gillette W, McCormick F, Esposito D.

J Biol Chem. 2020 Jan 24;295(4):1105-1119. doi: 10.1074/jbc.RA119.010934. Epub 2019 Dec 13.

5.

Erratum to: Sensitive Drug-Resistance Assays Reveal Long-Term Persistence of HIV-1 Variants with the K103N Nevirapine (NVP) Resistance Mutation in Some Women and Infants after the Administration of Single-Dose NVP: HIVNET 012.

Flys T, Nissley DV, Claasen CW, Jones D, Shi C, Guay LA, Musoke P, Mmiro F, Strathern JN, Jackson JB, Eshleman JR, Eshleman SH.

J Infect Dis. 2019 Nov 27. pii: jiz524. doi: 10.1093/infdis/jiz524. [Epub ahead of print] No abstract available.

PMID:
31776582
6.

Structures of N-terminally processed KRAS provide insight into the role of N-acetylation.

Dharmaiah S, Tran TH, Messing S, Agamasu C, Gillette WK, Yan W, Waybright T, Alexander P, Esposito D, Nissley DV, McCormick F, Stephen AG, Simanshu DK.

Sci Rep. 2019 Jul 19;9(1):10512. doi: 10.1038/s41598-019-46846-w.

7.

Membrane curvature sensing of the lipid-anchored K-Ras small GTPase.

Liang H, Mu H, Jean-Francois F, Lakshman B, Sarkar-Banerjee S, Zhuang Y, Zeng Y, Gao W, Zaske AM, Nissley DV, Gorfe AA, Zhao W, Zhou Y.

Life Sci Alliance. 2019 Jul 11;2(4). pii: e201900343. doi: 10.26508/lsa.201900343. Print 2019 Aug.

8.

Intercellular Transfer of Oncogenic KRAS via Tunneling Nanotubes Introduces Intracellular Mutational Heterogeneity in Colon Cancer Cells.

Desir S, Wong P, Turbyville T, Chen, Shetty M, Clark C, Zhai E, Romin Y, Manova-Todorova K, Starr TK, Nissley DV, Steer CJ, Subramanian S, Lou E.

Cancers (Basel). 2019 Jun 26;11(7). pii: E892. doi: 10.3390/cancers11070892.

9.

KRAS Prenylation Is Required for Bivalent Binding with Calmodulin in a Nucleotide-Independent Manner.

Agamasu C, Ghirlando R, Taylor T, Messing S, Tran TH, Bindu L, Tonelli M, Nissley DV, McCormick F, Stephen AG.

Biophys J. 2019 Mar 19;116(6):1049-1063. doi: 10.1016/j.bpj.2019.02.004. Epub 2019 Feb 15.

10.

Quantitative biophysical analysis defines key components modulating recruitment of the GTPase KRAS to the plasma membrane.

Lakshman B, Messing S, Schmid EM, Clogston JD, Gillette WK, Esposito D, Kessing B, Fletcher DA, Nissley DV, McCormick F, Stephen AG, Jean-Francois FL.

J Biol Chem. 2019 Feb 8;294(6):2193-2207. doi: 10.1074/jbc.RA118.005669. Epub 2018 Dec 17.

11.

Direct molecular dissection of tumor parenchyma from tumor stroma in tumor xenograft using mass spectrometry-based glycoproteomics.

Ye X, Luke BT, Wei BR, Kaczmarczyk JA, Loncarek J, Dwyer JE, Johann DJ, Saul RG, Nissley DV, McCormick F, Whiteley GR, Blonder J.

Oncotarget. 2018 May 29;9(41):26431-26452. doi: 10.18632/oncotarget.25449. eCollection 2018 May 29.

12.

RAS Proteins and Their Regulators in Human Disease.

Simanshu DK, Nissley DV, McCormick F.

Cell. 2017 Jun 29;170(1):17-33. doi: 10.1016/j.cell.2017.06.009. Review.

13.

Tumor RAS Gene Expression Levels Are Influenced by the Mutational Status of RAS Genes and Both Upstream and Downstream RAS Pathway Genes.

Stephens RM, Yi M, Kessing B, Nissley DV, McCormick F.

Cancer Inform. 2017 Jun 8;16:1176935117711944. doi: 10.1177/1176935117711944. eCollection 2017.

14.

Comparative proteomics of a model MCF10A-KRasG12V cell line reveals a distinct molecular signature of the KRasG12V cell surface.

Ye X, Chan KC, Waters AM, Bess M, Harned A, Wei BR, Loncarek J, Luke BT, Orsburn BC, Hollinger BD, Stephens RM, Bagni R, Martinko A, Wells JA, Nissley DV, McCormick F, Whiteley G, Blonder J.

Oncotarget. 2016 Dec 27;7(52):86948-86971. doi: 10.18632/oncotarget.13566.

15.

Structural basis of recognition of farnesylated and methylated KRAS4b by PDEδ.

Dharmaiah S, Bindu L, Tran TH, Gillette WK, Frank PH, Ghirlando R, Nissley DV, Esposito D, McCormick F, Stephen AG, Simanshu DK.

Proc Natl Acad Sci U S A. 2016 Nov 1;113(44):E6766-E6775. Epub 2016 Oct 17.

16.

Farnesylated and methylated KRAS4b: high yield production of protein suitable for biophysical studies of prenylated protein-lipid interactions.

Gillette WK, Esposito D, Abreu Blanco M, Alexander P, Bindu L, Bittner C, Chertov O, Frank PH, Grose C, Jones JE, Meng Z, Perkins S, Van Q, Ghirlando R, Fivash M, Nissley DV, McCormick F, Holderfield M, Stephen AG.

Sci Rep. 2015 Nov 2;5:15916. doi: 10.1038/srep15916.

17.

Mass spectrometry in cancer biomarker research: a case for immunodepletion of abundant blood-derived proteins from clinical tissue specimens.

Prieto DA, Johann DJ Jr, Wei BR, Ye X, Chan KC, Nissley DV, Simpson RM, Citrin DE, Mackall CL, Linehan WM, Blonder J.

Biomark Med. 2014;8(2):269-86. doi: 10.2217/bmm.13.101.

18.

Emergence of primary NNRTI resistance mutations without antiretroviral selective pressure in a HAART-treated child.

Machado ES, Afonso AO, Nissley DV, Lemey P, Cunha SM, Oliveira RH, Soares MA.

PLoS One. 2009;4(3):e4806. doi: 10.1371/journal.pone.0004806. Epub 2009 Mar 11.

19.

The human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor resistance mutation I132M confers hypersensitivity to nucleoside analogs.

Ambrose Z, Herman BD, Sheen CW, Zelina S, Moore KL, Tachedjian G, Nissley DV, Sluis-Cremer N.

J Virol. 2009 Apr;83(8):3826-33. doi: 10.1128/JVI.01968-08. Epub 2009 Feb 4.

20.

Characterization of novel non-nucleoside reverse transcriptase (RT) inhibitor resistance mutations at residues 132 and 135 in the 51 kDa subunit of HIV-1 RT.

Nissley DV, Radzio J, Ambrose Z, Sheen CW, Hamamouch N, Moore KL, Tachedjian G, Sluis-Cremer N.

Biochem J. 2007 May 15;404(1):151-7.

21.

Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency.

Halvas EK, Aldrovandi GM, Balfe P, Beck IA, Boltz VF, Coffin JM, Frenkel LM, Hazelwood JD, Johnson VA, Kearney M, Kovacs A, Kuritzkes DR, Metzner KJ, Nissley DV, Nowicki M, Palmer S, Ziermann R, Zhao RY, Jennings CL, Bremer J, Brambilla D, Mellors JW.

J Clin Microbiol. 2006 Jul;44(7):2612-4.

22.

Sensitive phenotypic detection of minor drug-resistant human immunodeficiency virus type 1 reverse transcriptase variants.

Nissley DV, Halvas EK, Hoppman NL, Garfinkel DJ, Mellors JW, Strathern JN.

J Clin Microbiol. 2005 Nov;43(11):5696-704.

23.

APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast.

Schumacher AJ, Nissley DV, Harris RS.

Proc Natl Acad Sci U S A. 2005 Jul 12;102(28):9854-9. Epub 2005 Jul 6.

24.

Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012.

Flys T, Nissley DV, Claasen CW, Jones D, Shi C, Guay LA, Musoke P, Mmiro F, Strathern JN, Jackson JB, Eshleman JR, Eshleman SH.

J Infect Dis. 2005 Jul 1;192(1):24-9. Epub 2005 Jun 1.

PMID:
15942890
25.

Hybrid Ty1/HIV-1 elements used to detect inhibitors and monitor the activity of HIV-1 reverse transcriptase.

Nissley DV, Boyer PL, Garfinkel DJ, Hughes SH, Strathern JN.

Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13905-10.

26.

HIV reverse transcription in yeast.

Nissley DV, Garfinkel DJ, Strathern JN.

Nature. 1996 Mar 7;380(6569):30. No abstract available.

PMID:
8598898
27.

Mutations in the inverted repeats of Tn3 affect binding of transposase and transposition immunity.

Nissley DV, Lindh F, Fennewald MA.

J Mol Biol. 1991 Mar 20;218(2):335-47.

PMID:
1849179
28.

Mutational analysis of the inverted repeats of Tn3.

Nissley DV, Lindh FG, Fennewald MA.

J Mol Biol. 1990 Jun 20;213(4):671-6.

PMID:
2162965

Supplemental Content

Loading ...
Support Center